Search Results for keywords:"National Cancer Institute"

The National Cancer Institute is considering granting an exclusive patent license to Senti Bio for developing and commercializing certain therapies that target CD33-expressing cancers. These therapies involve using specially engineered immune cells, like T cells and NK cells, to recognize and attack cancer cells marked by the CD33 protein, commonly found in acute myeloid leukemia. People interested in this license must submit their comments or applications by January 29, 2021. The patent rights involved have been assigned to the U.S. government, and the license could apply worldwide.

The National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH), is considering giving Ziopharm Oncology, Inc. an exclusive patent license to develop and market certain cancer therapies. These therapies involve using a patient's own T cells that are engineered to target specific mutations in the P53 gene, which is commonly mutated in many cancers. The license will cover treatments made through a method known as transposon-mediated gene transfer but will not include those made using CRISPR technology. Interested parties have until February 9, 2021, to submit comments or license applications.

The National Cancer Institute is holding a closed meeting on March 9, 2021, to evaluate the personal qualifications, performance, and competence of individual investigators at the institute. This meeting, organized by the Board of Scientific Counselors, will take place virtually from 11:00 a.m. to 5:40 p.m. The meeting is not open to the public to protect the privacy of the individuals being evaluated. For more information, Brian E. Wojcik, Ph.D., can be contacted.

The National Cancer Institute is holding a closed meeting on April 10, 2025, to review and evaluate grant applications. This meeting is part of the NCI Transition Career Development Awards and Institutional Research and Education Training Grants. It will be held virtually from 9:00 a.m. to 7:00 p.m. The meeting will remain closed to the public to protect personal and confidential information involved in the discussions.

The National Cancer Institute has announced a change in the date for a special meeting initially planned for February 24, 2025. The meeting will now take place on March 10, 2025, from 11 a.m. to 3 p.m. The format, location, and timing of the meeting will remain unchanged, and it will be conducted virtually. This meeting will be closed to the public.

The National Cancer Institute, part of the National Institutes of Health, has announced several upcoming meetings. These meetings, scheduled between January and March 2025, are intended to evaluate grant applications and contract proposals related to cancer research. The meetings will be closed to the public to protect confidential information and personal privacy. Each meeting will take place virtually, and further details, including contact information for scientific review officers, are provided for each session.

The National Cancer Institute has announced several upcoming closed meetings as required by the Federal Advisory Committee Act. These meetings will be virtual and are set to review grant applications and contract proposals, focusing on areas like cancer intervention, training, and research awards. The meetings are closed to the public to protect trade secrets and personal privacy. Each meeting will involve a committee of experts and will address different research and funding topics.

The National Cancer Institute is hosting a virtual meeting of the Clinical Trials and Translational Research Advisory Committee on March 17, 2021. The meeting will discuss strategic plans for the Institute's clinical and translational research programs. It is open to the public and can be accessed via the NIH webcasting site. For special accommodations or to submit comments, individuals can contact Sheila A. Prindiville at the details provided in the notice.

The National Cancer Institute is holding a meeting on April 4, 2025, to review and evaluate grant applications related to cancer research in physical sciences oncology. This meeting, held virtually, will be closed to the public due to the sensitive nature of the discussions, which may disclose confidential information. The meeting's contact person is Saejeong J. Kim, Ph.D., and it will take place from 11:30 a.m. to 4:30 p.m. at the National Cancer Institute in Rockville, Maryland.

The National Cancer Institute has announced that there will be closed meetings where grant applications will be reviewed. These meetings are not open to the public to protect trade secrets, personal privacy, and commercial property. One meeting will happen on April 14, 2025, focusing on reviewing specific cancer research program projects. Another meeting is scheduled for April 16-17, 2025, to evaluate informatics technologies for cancer research. The meetings will take place virtually, and the responsible contacts are Leila B. Toulabi, Ph.D., and Susan Lynn Spence, Ph.D.